1. A nonrandomized trial of vitamin D supplementation for Barrett's esophagus.
- Author
-
Linda C Cummings, Prashanthi N Thota, Joseph E Willis, Yanwen Chen, Gregory S Cooper, Nancy Furey, Beth Bednarchik, Bronia M Alashkar, John Dumot, Ashley L Faulx, Stephen P Fink, Adam M Kresak, Basel Abusneineh, Jill Barnholtz-Sloan, Patrick Leahy, Martina L Veigl, Amitabh Chak, and Sanford D Markowitz
- Subjects
Medicine ,Science - Abstract
Vitamin D deficiency may increase esophageal cancer risk. Vitamin D affects genes regulating proliferation, apoptosis, and differentiation and induces the tumor suppressor 15-hydroxyprostaglandin dehydrogenase (PGDH) in other cancers. This nonrandomized interventional study assessed effects of vitamin D supplementation in Barrett's esophagus (BE). We hypothesized that vitamin D supplementation may have beneficial effects on gene expression including 15-PGDH in BE.BE subjects with low grade or no dysplasia received vitamin D3 (cholecalciferol) 50,000 international units weekly plus a proton pump inhibitor for 12 weeks. Esophageal biopsies from normal plus metaplastic BE epithelium and blood samples were obtained before and after vitamin D supplementation. Serum 25-hydroxyvitamin D was measured to characterize vitamin D status. Esophageal gene expression was assessed using microarrays.18 study subjects were evaluated. The baseline mean serum 25-hydroxyvitamin D level was 27 ng/mL (normal ≥30 ng/mL). After vitamin D supplementation, 25-hydroxyvitamin D levels rose significantly (median increase of 31.6 ng/mL, p
- Published
- 2017
- Full Text
- View/download PDF